A5102805027- CAR-T cell therapy research
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Biosimilars and Bioanalytical Methods
- Advancements in Semiconductor Devices and Circuit Design
- Caveolin-1 and cellular processes
- Osteoarthritis Treatment and Mechanisms
- CRISPR and Genetic Engineering
- Mesenchymal stem cell research
- RNA Interference and Gene Delivery
- Adipokines, Inflammation, and Metabolic Diseases
- Periodontal Regeneration and Treatments
- Pancreatitis Pathology and Treatment
- Multiple Myeloma Research and Treatments
- Pancreatic function and diabetes
- Nanowire Synthesis and Applications
- Retinoids in leukemia and cellular processes
- Animal Genetics and Reproduction
- Immune Cell Function and Interaction
- Cytokine Signaling Pathways and Interactions
- Regulation of Appetite and Obesity
- Robotic Path Planning Algorithms
- Smart Parking Systems Research
- T-cell and B-cell Immunology
- Cancer Research and Treatments
Shanghai Jiao Tong University
2013-2021
Shanghai Children's Hospital
2011-2020
Liuzhou General Hospital
2020
First Affiliated Hospital of GuangXi Medical University
2018
Guangxi Medical University
2018
Shanghai Cell Therapy Research Institute
2017
Cellular Biomedicine Group (United States)
2015
Abstract Programmed cell death protein-1 (PD-1)-mediated immunosuppression has been proposed to contribute the limited clinical efficacy of chimeric antigen receptor T (CAR-T) cells in solid tumors. We generated PD-1 and (TCR) deficient mesothelin-specific CAR-T (MPTK-CAR-T) using CRISPR-Cas9 technology evaluated them a dose-escalation study. A total 15 patients received one or more infusions MPTK-CAR-T without prior lymphodepletion. No dose-limiting toxicity unexpected adverse events were...
Although chimeric antigen receptor T-cell (CAR-T) therapy development for B-cell malignancies has made significant progress in the last decade, broadening success to treating acute lymphoblastic leukemia (T-ALL) been limited. We conducted two clinical trials verify safety and efficacy of GC027, an "off-the-shelf" allogeneic CAR-T product targeting antigen, CD7. Here, we report 2 patients as case reports with relapsed/refractory T-ALL who were treated GC027.Both reported here open-label...
Abstract To improve clinical outcomes and shorten the vein-to-vein time of chimeric antigen receptor T (CAR-T) cells, we developed FasT CAR-T (F-CAR-T) next-day manufacturing platform. We report preclinical first-in-human studies evaluating safety, feasibility, preliminary efficacy CD19 F-CAR-T in B-cell acute lymphoblastic leukemia (B-ALL). cells demonstrated excellent proliferation with a younger cellular phenotype, less exhaustion, more effective tumor elimination compared to conventional...
8005 Background: GC012F is a chimeric antigen receptor (CAR)-T cell therapy with B maturation (BCMA) and CD19 dual-target developed on the novel FasT CAR-T platform enabling 22-36 h manufacturing. Our previous results were presented at ASCO EHA 2022 for 29 pts (NCT04236011; NCT04182581), which demonstrated treatment led to deep durable response in RRMM pts. Furthermore, initial showed that considerable efficacy safety high-risk transplant-eligible newly diagnosed MM (Blood 2022; 140...
Although a number of studies have reported efficacy autologous adipose-derived mesenchymal stem cells (AD-MSCs) in treating osteoarthritis (OA) no reliable evidences demonstrate whether allogeneic AD-MSCs can efficiently block OA progression large animal model. This study explored the and survival combined with hyaluronic acid (HA) after intra-articular (IA) injection sheep model, which were conventionally established by anterior cruciate ligament resection medial meniscectomy. Allogeneic...
Mesenchymal stem cells (MSCs) are known to have the potential for articular cartilage regeneration, and suggested treatment of osteoarthritis (OA). Here, we investigated whether intra-articular injection xenogeneic human adipose-derived mesenchymal progenitor (haMPCs) promoted repair in rabbit OA model engrafted into cartilage. The haMPCs were cultured vitro, phenotypes differentiation characteristics evaluated. was induced surgically by anterior cruciate ligament transection (ACLT) medical...
Abstract Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targeting CAR-T product GC007F manufactured next-day (FasTCAR-T cells) and administered R/R B-ALL. A total of 21 over 14 years age CD19 + B-ALL were screened, enrolled infused a single infusion at three...
Abstract Introduction: Patients with T cell malignancies usually have high relapse and mortality rates. Due to shared common surface antigen potential contamination by malignant cells, development of CAR-T therapies for r/r T-ALL has been lagged, regardless the costly lengthy process autologous production. To overcome these challenges, we developed a universal platform (TruUCAR™) that displayed superior expansion in patients without using preconditioning biologics such as αCD52 antibody....
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: GC012F is a B cell maturation antigen (BCMA) CD19 dual-targeting chimeric receptor (CAR)-T developed on the novel FasTCAR-T platform enabling 22-36 h manufacturing. Our previous results presented at ASCO EHA 2022 for 29 pts (NCT04236011; NCT04182581), demonstrated that treatment led to deep durable response in RRMM pts. Furthermore, initial showed considerable efficacy safety of newly diagnosed high-risk...
Proinflammatory cytokines are well-known to inhibit insulin signaling result in resistance. IL-1α is also one of the proinflammatory cytokines, but mechanism how induces resistance remains unclear. We have now examined effects on 3T3-L1 adipocytes. Prolonged treatment for 12 24 hours partially decreased protein levels as well insulin-stimulated tyrosine phosphorylation IRS-1 and Akt phosphorylation. mRNA SOCS3, an endogenous inhibitor signaling, was dramatically augmented 4 after treatment....
3013 Background: Patients with r/r T-ALL usually have high relapse and mortality rates. Due to shared common surface antigen potential contamination by malignant cells, development of autologous CAR-T therapies for has been lagged, regardless the costly lengthy process production. Through targeting CD7, a T cell highly expressed in >95% samples, universal product GC027 developed using lentivirus CRISPR/Cas9 system demonstrated anti-leukemia ability murine xenograft model. Methods:...
3038 Background: Our previous phase I study with MPTK-CAR-T (mesothelin-directed 28ζ CAR-T cells PD-1 and TCR disruption by CRISPR-Cas9 system) demonstrated feasibility safety of CRISPR-mediated inactivation in cells, suggested the natural is beneficial for proliferation solid tumors. Based on these observations, we initiated a pilot dose escalation to investigate mesothelin-directed only CRISPR (termed as GC008t) patients mesothelin-positive advanced tumors (NCT03747965). Methods: On data...
Automatic parking is a useful ADAS for cars. This paper proposes path planning method automatic in narrow space. First, fast A* algorithm solves discrete points between given pair of initial and target vehicle positions. Then, screening obtains "anchor points" oriented space parking, based on which continuous smooth trajectories are generated. Simulation experiments demonstrate that the proposed can effectively perform under various conditions, outperforms baseline methods terms success rate time.
Lentiviral vectors (LVs) have enhancer activity and/or transcriptional read-through (EATRT) properties that can lead to the activation of adjacent genes. Consequently, patients may be at increased risk for adverse effects if such are used clinically.In present study, we assessed abilities different "pro-LV"-like constructs with respect decreasing its EATRT, including "pro-LV" vector bearing a chimeric ΔLTR human foamy virus R-U5 region replaced by an LV (HF).By analyzing EATRT transfected in...
Abstract T-cell acute lymphoblastic leukemia (T-ALL) represents an area of high unmet medical needs. Once relapsed, patients have limited treatment options and usually a poor prognosis. T-ALL antigens such as CD7 is extensively expressed in normal T cells natural killer (NK) cells, extending the success CAR-T therapy to cell malignancies was challenged by fratricide, production cost, long lagging time potential product contaminations. GC027 “off-the-shelf” allogeneic targeted therapeutic for...